The goal of the Hematologic Malignancies Research Program is to stimulate and support interactive basic, translational and clinical research on the pathogenesis and therapy of malignant blood disorders across the participating institutions of the center.
Our researchers hope to improve the diagnosis, treatment and prognosis of patients with these diseases. The program is designed to take maximum advantage of the diverse research interests and expertise of its members and will stimulate multidisciplinary and interdisciplinary collaborations.
The program emphasizes:
- Defining molecular pathways critical to the pathogenesis of hematologic malignancies, validating these pathways in preclinical models, and carrying out preclinical and clinical testing of drugs targeting these pathways
- Developing novel cellular therapies to improve outcomes for patients with hematologic malignancies
The Hematologic Malignancies Program serves as an important nodal point within the Cancer Center, facilitating studies of animal modeling and targeted therapeutics. It also provides a center for interactions with the basic science programs involving cancer genetics, cancer cell biology and immunology.
The overall goal is to accelerate and facilitate the translation and application of new basic science knowledge in normal and malignant hematopoiesis to patient care.
Andreas Klein, MD, Director
Andy Evens, MD, Co-Leader
Kristine Burgess, DVM, MS, DACVIM, Co-Leader
David Schenkein, MD
Robert Schwartz, MD, Emeritus faculty
Hematologic Malignancies Program